CO2021017708A2 - Ligandos de antígeno de membrana específico de próstata (psma) y sus usos - Google Patents

Ligandos de antígeno de membrana específico de próstata (psma) y sus usos

Info

Publication number
CO2021017708A2
CO2021017708A2 CONC2021/0017708A CO2021017708A CO2021017708A2 CO 2021017708 A2 CO2021017708 A2 CO 2021017708A2 CO 2021017708 A CO2021017708 A CO 2021017708A CO 2021017708 A2 CO2021017708 A2 CO 2021017708A2
Authority
CO
Colombia
Prior art keywords
psma
ligands
specific membrane
membrane antigen
prostate specific
Prior art date
Application number
CONC2021/0017708A
Other languages
English (en)
Spanish (es)
Inventor
Lorenza Fugazza
Maurizio F Mariani
Daniela Chicco
Martin Gilbert Pomper
Sangeeta Ray
Original Assignee
Univ Johns Hopkins
Advanced Accelerator Applications Italy Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins, Advanced Accelerator Applications Italy Srl filed Critical Univ Johns Hopkins
Publication of CO2021017708A2 publication Critical patent/CO2021017708A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/38—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
CONC2021/0017708A 2019-07-02 2021-12-23 Ligandos de antígeno de membrana específico de próstata (psma) y sus usos CO2021017708A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19184015 2019-07-02
PCT/EP2020/068386 WO2021001360A1 (en) 2019-07-02 2020-06-30 Prostate specific membrane antigen (psma) ligands and uses thereof

Publications (1)

Publication Number Publication Date
CO2021017708A2 true CO2021017708A2 (es) 2022-05-20

Family

ID=67145647

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0017708A CO2021017708A2 (es) 2019-07-02 2021-12-23 Ligandos de antígeno de membrana específico de próstata (psma) y sus usos

Country Status (16)

Country Link
US (1) US20230226227A1 (cg-RX-API-DMAC7.html)
EP (1) EP3993837A1 (cg-RX-API-DMAC7.html)
JP (2) JP7805170B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220044496A (cg-RX-API-DMAC7.html)
CN (3) CN120441497A (cg-RX-API-DMAC7.html)
AR (1) AR119331A1 (cg-RX-API-DMAC7.html)
AU (3) AU2020299974A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021026812A2 (cg-RX-API-DMAC7.html)
CA (1) CA3144557A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003525A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021017708A2 (cg-RX-API-DMAC7.html)
IL (1) IL289039B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022000136A (cg-RX-API-DMAC7.html)
PH (1) PH12021553284A1 (cg-RX-API-DMAC7.html)
TW (1) TW202114742A (cg-RX-API-DMAC7.html)
WO (1) WO2021001360A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297323A (en) * 2020-04-29 2022-12-01 Novartis Ag Methods for radiological labeling of psma-binding ligands and their kits
WO2022108992A1 (en) * 2020-11-17 2022-05-27 The Johns Hopkins University Prostate-specific membrane antigen (psma)-targeted prodrug for selective killing of cells expressing psma
EP4746926A2 (en) 2023-07-21 2026-05-27 Novartis AG Psma-targeting radioligand treatment regimen
WO2025125469A1 (en) 2023-12-13 2025-06-19 Swiss Rockets Ag Combination therapy using psma-targeted radiopharmaceuticals and an inhibitor of pi3k, akt, and/or mtor
WO2026125645A1 (en) 2024-12-12 2026-06-18 Swiss Rockets Ag Radiopharmaceuticals for use in the treatment of high-risk localized prostate cancer
WO2026159621A1 (en) 2025-01-23 2026-07-30 Novartis Ag Treatment regimen using psma-binding radioligands in combination with androgen receptor pathway inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2415709A1 (en) 2000-07-11 2003-01-10 Bml, Inc. Remedies for bone diseases
JP5843338B2 (ja) * 2011-08-05 2016-01-13 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 放射標識された前立腺特異的膜抗原阻害剤
AU2014336638C1 (en) * 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
KR20250057132A (ko) * 2016-03-22 2025-04-28 더 존스 홉킨스 유니버시티 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제
US11478558B2 (en) * 2017-05-30 2022-10-25 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
WO2019157037A1 (en) * 2018-02-06 2019-08-15 The Johns Hopkins University Psma targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy
US20210338846A1 (en) * 2018-07-30 2021-11-04 The Johns Hopkins University Competitive prostate-specific membrane antigen (psma) binding agents for reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy

Also Published As

Publication number Publication date
JP2025165975A (ja) 2025-11-05
KR20220044496A (ko) 2022-04-08
AR119331A1 (es) 2021-12-09
CN114341118A (zh) 2022-04-12
AU2025271182A1 (en) 2025-12-18
JP7805170B2 (ja) 2026-01-23
CN120441497A (zh) 2025-08-08
AU2024200850B2 (en) 2025-09-04
TW202114742A (zh) 2021-04-16
PH12021553284A1 (en) 2022-08-01
AU2024200850A1 (en) 2024-02-29
MX2022000136A (es) 2022-04-27
WO2021001360A1 (en) 2021-01-07
CN120441498A (zh) 2025-08-08
AU2020299974A1 (en) 2022-01-27
JP2022538478A (ja) 2022-09-02
IL289039B2 (en) 2026-07-01
BR112021026812A2 (pt) 2022-02-22
IL289039B1 (en) 2026-03-01
CL2021003525A1 (es) 2022-10-21
US20230226227A1 (en) 2023-07-20
IL289039A (en) 2022-02-01
CA3144557A1 (en) 2021-01-07
EP3993837A1 (en) 2022-05-11

Similar Documents

Publication Publication Date Title
CL2021003525A1 (es) Ligandos de antígeno de membrana específico de próstata (psma) y sus usos
CO2023004252A2 (es) Anticuerpos anti-ceacam5 y conjugados y usos de los mismos
CL2022003085A1 (es) Anticuerpos contra sars-cov-2
EA201890282A1 (ru) Улучшенные ингибиторы простатического специфического мембранного антигена (псма), меченные 18f, и их применение в качестве визуализирующих агентов при раке простаты
MX2020006112A (es) Complejo que comprende un compuesto orientado a psma vinculado a un radionucleido de plomo o torio.
AR110056A2 (es) Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos
CL2017003021A1 (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos.
PE20190327A1 (es) Complejos radio-farmaceuticos
EA202092306A1 (ru) Анти-cd24 композиции и их применения
MY194484A (en) Labeled Inhibitors of Prostate Specific Membrane Antigen (PSMA), Their use as Imaging Agents and Pharmaceutical Agents for the Treatment of Prostate Cancer
ECSP099619A (es) Anticuerpos anti-robo4 y sus usos
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
MX387596B (es) Degradadores selectivos del receptor de estrógeno y sus usos.
ECSP22044316A (es) Mol?culas de fusi?n del ecd de siglec-9 y m?todos de uso de estas
PE20200866A1 (es) Composiciones que contienen conjugados de analogos cannabinoides y metodos de uso
EA201891473A1 (ru) Комбинированная терапия
MX2022000654A (es) Sistemas fluorescentes para imagenes biologicas y usos de los mismos.
CL2022000894A1 (es) Moduladores atf6 y sus usos.
MX2022005358A (es) Composiciones de copolímero de bloque sensibles al ph, micelas, y métodos de uso.
MX2021014292A (es) Formulaciones de agentes de imagen de psma.
CO2020010043A2 (es) Marcadores de la enfermedad de farber y usos de estos
AR107298A1 (es) Método de purificación
MX387020B (es) Fluido terapeutico peritoneal.
UY37167A (es) Complejos radiofarmacéuticos
EA201791897A1 (ru) α-МИКРОГЛОБУЛИН ДЛЯ ИСПОЛЬЗОВАНИЯ В ЗАЩИТЕ ПОЧЕК ПРИ РАДИОНУКЛИДНОЙ ТЕРАПИИ